In this study, we focused on longitudinal quantitative PET/CT imaging with VAP-1-targeting [68Ga]Ga-DOTA-Siglec-9 to assess the pharmacodynamic effect of the novel tumor-targeting FAP-IL2v immunocytokine in mice bearing B16-FAP melanoma tumors. This evidence concerns the gene FAP and melanoma.